Black Diamond Therapeutics
BDTX
104 hedge funds and large institutions have $82M invested in Black Diamond Therapeutics in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 21 closing their positions.
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
4% more call options, than puts
Call options by funds: $229K | Put options by funds: $221K
0.78% more ownership
Funds ownership: 66.45% → 67.23% (+0.78%)
0% more funds holding
Funds holding: 104 → 104 (0)
11% less capital invested
Capital invested by funds: $92M → $82M (-$9.99M)
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.71M |
| 2 |
Renaissance Technologies
New York
|
+$1.65M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.31M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.21M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$2.54M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$2.11M |
| 3 |
Jane Street
New York
|
-$2.06M |
| 4 |
D.E. Shaw & Co
New York
|
-$694K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$656K |
BDTX Hedge Fund Activity: Q1 2026 in Review
104 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2026, worth a combined $82M — down 11% from $92M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BDTX positions and 21 closed out — a net gain of 2 holders — while 30 added to existing stakes and 34 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $1.71M. The largest seller was Siren LLC, exiting entirely with an estimated $2.54M sold.
- 104 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $82M of Black Diamond Therapeutics stock for Q1 2026, down 11% quarter-over-quarter.
- 23 funds opened new Black Diamond Therapeutics positions in Q1 2026 and 21 closed out, a net change of +2 holders.
- The largest Black Diamond Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $1.71M added.
- The largest Black Diamond Therapeutics seller in Q1 2026 was Siren LLC, an estimated $2.54M sold.
Based on aggregated 13F filings for Q1 2026.